BGF MDI HFO 320/14.4/9.6μg + BGF MDI HFA 320/14.4/9.6 μg + Placebo MDI HFA
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
COPD (Chronic Obstructive Pulmonary Disease)
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Trial Timeline
Jan 11, 2024 → Aug 12, 2025
NCT ID
NCT06075095About BGF MDI HFO 320/14.4/9.6μg + BGF MDI HFA 320/14.4/9.6 μg + Placebo MDI HFA
BGF MDI HFO 320/14.4/9.6μg + BGF MDI HFA 320/14.4/9.6 μg + Placebo MDI HFA is a phase 3 stage product being developed by AstraZeneca for COPD (Chronic Obstructive Pulmonary Disease). The current trial status is completed. This product is registered under clinical trial identifier NCT06075095. Target conditions include COPD (Chronic Obstructive Pulmonary Disease).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06075095 | Phase 3 | Completed |
Competing Products
20 competing products in COPD (Chronic Obstructive Pulmonary Disease)